Aranesp

Type: Product
Name: Aranesp
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Human medicines European public assessment report (EPAR): Aranesp, darbepoetin alfa, Revision: 32, Authorised

This is a summary of the European public assessment report (EPAR) for Aranesp. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its ... [Published European Medicines Agency - 10 hours ago]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Amgen reports bumper results... then wields job axe new

Amgen is the world's biggest maker of biologic drugs– 31 July 2014Biologic drug-maker Amgen is to shed 12% to 15% of its worldwide workforce and close four sites, despite reporting stellar second-quarter results that trounced Wall Street expectations ... [Published Belfast Telegraph - 14 hours ago]
First reported Jul 30 2014 - Updated 23 hours ago - 1 reports

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

Amgen (Nasdaq: AMGN), the largest global independent biotech firm, reported a 23% leap in second-quarter 2014 profit and an 11% rise in revenues, but surprised by announcing a 15% cut in its worldwide workforce and the closure of four sites.Net income ... [Published Pharma Letter - Jul 30 2014]
Entities: Amgen Inc, Enbrel, XGEVA
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Biotech giant axes up to 2,900 jobs

Biologic drug-maker Amgen is to shed 12 to 15% of its worldwide workforce and close four sites, despite reporting stellar second-quarter results that trounced Wall Street expectations.Amgen, which has more than 500 staff working at its UK sites in Cambridge ... [Published BT.com - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Clinical Trial Will Evaluate Drug's Ability to Protect Normal Cells During Chemotherapy

Chemotherapy is like nuking the body with chemicals. It kills good and bad cells alike, which is why cancer patients undergoing treatment get fatigued and suffer through a whole host of side effects. A little startup built around research at the University ... [Published American Journal of Managed Care - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Amgen’s Second-Quarter Earnings Look Strong

at 6:28 am ESTClick Ticker to See live coverageAmgen, Inc. ( AMGN ) will announce earnings for the second quarter of its 2014 fiscal year (2QFY14) on July 29 after markets close. Its earnings per share are expected to register a 12.4% increase year-over-year ... [Published Bidness Etc - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

G1, Out to Shield Body From Chemo, Heads to First Clinical Test

Chemotherapy is like nuking the body with chemicals. It kills good and bad cells alike, which is why cancer patients undergoing treatment get fatigued and suffer through a whole host of side effects. A little startup built around research at the University ... [Published Xconomy - Jul 28 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Puma Biotechnology: Another Jackpot For Investors

Investors who purchased shares in Puma Biotechnology Inc. before the closing of Wall Street on Tuesday—at around $60 or better at the 52-week low of $33.70 — hit the jackpot.The stock was trading north of $230 on Wednesday, an overnight gain of  293% ... [Published Forbes.com - Jul 23 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Cipla collaborates with Hetero to launch its second biosimilar drug Darbepoetin alfa

Is indicated for the treatment of anaemia caused due to chronic kidney diseaseCipla has collaborated with Hetero to launch a biosimilar of the drug Darbepoetin alfa under the brand name ‘Actorise’. The collaboration stands as a multi-partner co-marketing ... [Published Express Pharma - Jul 07 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 1 reports

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

Cipla (BSE: 500087) has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin alfa, US biotech major Amgen's (Nasdaq: AMGN) anemia drug Aranesp, under the brand name Actorise.The collaboration stands as a multi-partner ... [Published Pharma Letter - Jun 30 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Hetero Launches Darbepoetin Alfa, a Much Needed Biosimilar Anemia Treatment in India

India PRwire2014-06-24The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product in India, darbepoetin ... [Published BizWire Express - Jun 24 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 1 reports

Hetero Launches Darbepoetin Alfa, a Much Needed Biosimilar Anemia Treatment in India

HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product ... [Published Marketwire - Breaking News Releases - Jun 18 2014]

Quotes

Research head, Sean Harper, said: "We have an unprecedented number of late-stage programmes rolling through at the moment."
...growth through the first half of 2014 affirms the underlying strength of our business," said Robert Bradway, chairman and chief executive, adding: "We are making excellent progress in advancing our pipeline as we prepare to launch a number of promising new innovative medicines. From a position of strength, we have announced today restructuring initiatives that will allow us to reallocate resources to invest in our upcoming launches and drive growth."
"We view the restructuring plan and 15% workforce reduction announced as a positive that will help the company improve its cost structure while continuing to invest in the pipeline and key product launches" Citigroup analyst Dr Yaron Werber wrote to investors
Transparency Market Research published a new report "Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" to its report store...

More Content

All (28) | News (25) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Human medicines European public assessment repo... [Published European Medicines Agency - 10 hours ago]
Amgen reports bumper results... then wields job... [Published Belfast Telegraph - 14 hours ago]
Amgen’s 2nd-qtr beats expectations, but firm sl... [Published Pharma Letter - Jul 30 2014]
Amgen (AMGN) CEO Bob Bradway on Q2 2014 Results... [Published Seeking Alpha - Jul 30 2014]
Biotech giant axes up to 2,900 jobs [Published BT.com - Jul 30 2014]
Biotech drugmaker Amgen laying off at least 2,400 [Published Kentucky.com - Jul 30 2014]
Clinical Trial Will Evaluate Drug's Ability to ... [Published American Journal of Managed Care - Jul 28 2014]
Will Amgen (AMGN) Disappoint This Earnings Season? [Published Zacks.com - Jul 28 2014]
Amgen’s Second-Quarter Earnings Look Strong [Published Bidness Etc - Jul 28 2014]
G1, Out to Shield Body From Chemo, Heads to Fir... [Published Xconomy - Jul 28 2014]
Biological Drugs Market: Global Industry Analys... [Published PRWeb - Jul 25 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Jul 25 2014]
Puma Biotechnology: Another Jackpot For Investors [Published Forbes.com - Jul 23 2014]
XTL Hopes To Begin Major Lupus Trial Next Year [Published Seeking Alpha - Jul 22 2014]
Monday Moves—July 21, 2014 [Published Medical Marketing And Media - Jul 22 2014]
Global Biological Drugs Market is Expected to R... [Published Wall Street Business Network - Jul 16 2014]
Cipla collaborates with Hetero to launch its se... [Published Express Pharma - Jul 07 2014]
Cipla links with Hetero for biosimilar Aranesp;... [Published Pharma Letter - Jun 30 2014]
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published BizWire Express - Jun 24 2014]
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
Preemption. Beautiful, Beautiful Preemption [Published Drug and Device Law - Jun 09 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
Amgen net rises by 30% to $1,021 mn in Q4 [Published PharmaBiz - Jan 30 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
The Corporate Whistleblower Center Now Urges Lo... [Published PRWeb - Oct 16 2013]
Amgen accused of improper marketing practices [Published Topnews.in - Dec 19 2012]
Amgen commits to two more years as Tour of Cali... [Published Velonation - Aug 05 2011]
Secrecy Surrounds the Development of Tests to D... [Published Genetic Engineering News - Aug 04 2011]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product ...
Preemption. Beautiful, Beautiful Preemption [Published Drug and Device Law - Jun 09 2014]
The test for determining whether a state law claim is impliedly preempted is whether or not the claim would exist in the absence of the FDCA. Rarely do we drug and device law bloggers read such a pleasing sentence.  It’s lyrical.  It reads like romance ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.